Press release

85th Annual General Meeting of Galenica Ltd.:
Shareholders approve all proposals submitted by the Board of Directors

Thursday, 2 May 2013, ↓ directly to download

At the 85th Annual General Meeting of Galenica Ltd., the shareholders approved all the proposals submitted by the Board of Directors. Dr. Sylvie Grégoire was newly elected to the Board of Directors. The remuneration report was approved by almost 92%.

The 85th Annual General Meeting of Galenica Ltd. held today in Bern was attended by 419 shareholders, representing in total 74.1% of the registered voting shares of Galenica Ltd.

The shareholders gave their support to all of the Board of Directors’ proposed resolutions on the agenda: the General Meeting approved the Annual Report and Financial Statements for 2012 for Galenica Ltd. and the Galenica Group and gave discharge to the members of the Board and the Corporate Executive Committee for the financial year 2012. The remuneration report, which was submitted for an advisory vote to the shareholders for the sixth time, was approved by almost 92%.

Election to the Board of Directors
Dr. Sylvie Grégoire was elected as a new member of the Board of Directors for a three-year term of office. Sylvie Grégoire has a doctorate in pharmacy from the State University of New York in Buffalo, New York and brings over 20 years of international experience in the biotechnology and pharmaceutical industry to the board. Until recently Dr. Grégoire was President of Shire Human Genetic Therapies, prior to this she previously worked in various roles at companies including Biogen Inc. and Merck & Company, was a member of the board of directors of several companies in the US and Canada and has sat on the boards of various charitable organisations.

Prof. Dr. Michel Burnier, Dr. Hans Peter Frick and This E. Schneider, who has been Deputy Chairman since January 2013, were all re-elected for a three-year term of office. Kurt Briner was re-elected for a one-year term, as he will reach the age limit in 2014.

The dividend of CHF 11.00 (prior year: CHF 9.00, +22.2%) proposed by the Board was also approved and will be paid to shareholders on 10 May 2013.

The next Annual General Meeting of Galenica Ltd. will take place on 8 May 2014.

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).


Christina Hertig

Christina Hertig

Head of Corporate Communications

Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

+41 58 852 85 17
+41 58 852 85 58

Send link

Send as link